Pharming Group (PHGUF) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Pharming Group (OTCMKTS:PHGUF) from a buy rating to a hold rating in a report published on Saturday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

Other research analysts also recently issued reports about the company. Roth Capital reaffirmed a buy rating on shares of Pharming Group in a research note on Wednesday. ValuEngine lowered Pharming Group from a hold rating to a sell rating in a report on Friday, December 1st.

Pharming Group (PHGUF) traded down $0.06 during mid-day trading on Friday, reaching $1.55. The company had a trading volume of 611 shares, compared to its average volume of 6,527. Pharming Group has a fifty-two week low of $0.30 and a fifty-two week high of $1.96. The company has a debt-to-equity ratio of 11.47, a quick ratio of 0.99 and a current ratio of 1.31.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.

Leave a Reply